Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 10/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211504 | 0.93 | PDE5A (0.53) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6214601 | 0.92 | KMT2A (0.62) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6211500 | 0.91 | KMT2A (0.51) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6217377 | 0.91 | MAPT (0.45) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6211516 | 0.90 | MAPT (0.50) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6215341 | 0.89 | KMT2A (0.41) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6214813 | 0.87 | HTT (0.46) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6218405 | 0.86 | MAPT (0.46) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6213558 | 0.85 | PRKCI (0.49) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6796696 | 0.85 | PTPN12 (0.48) | KMT2AMEN1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351962-B1 | THIENOPYRIMIDINE | MERCK PATENT GMBH (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-6780867-B2 | THEY EXHIBIT SPECIFIC INHIBITION OF CGMP PHOSPHODIESTERASE (PDE V) | MERCK PATENT GMBH (DE) | 2004-08-24 | — | — | US | disclosed |
| US-20030187260-A1 | Thienopyrimidines | MERCK PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187260-A1 | Thienopyrimidines | TYMP, DPYD, IMPDH1 | KMT2A 3197/4885MEN1 2082/4885MAPT 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.